Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.46 |
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657497 | 0.85 | CALCRL (0.44) | CALCRLELANERAMP1RENCAPN1 | |
| SCHEMBL21312750 | 0.82 | XIAP (0.55) | CALCRLXIAPELANERENACE | |
| SCHEMBL30399601 | 0.81 | ACE (0.45) | RENACE | |
| SCHEMBL5065490 | 0.81 | XIAP (0.48) | CALCRLXIAPELANERAMP1REN | |
| SCHEMBL5065494 | 0.81 | XIAP (0.48) | CALCRLXIAPELANERAMP1REN | |
| SCHEMBL29609081 | 0.80 | CALCRL (0.46) | CALCRLXIAPRENCAPN1CTSD | |
| SCHEMBL29801921 | 0.80 | CALCRL (0.51) | CALCRLRAMP1CTSDBACE1 | |
| SCHEMBL30596283 | 0.79 | CALCRL (0.45) | CALCRLXIAPRENACEMLX | |
| SCHEMBL31500765 | 0.78 | CALCRL (0.51) | CALCRLXIAPRAMP1CAPN1 | |
| SCHEMBL29521253 | 0.78 | CALCRL (0.49) | CALCRLXIAPRAMP1RENCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CALCRL 3211/4885XIAP 1307/4885ELANE 204/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CALCRL 3211/4885XIAP 1307/4885ELANE 204/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CALCRL 3211/4885XIAP 1307/4885ELANE 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.